CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Genmab A/S (GMAB) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Genmab A/S (GMAB)

Pharmaceutical Preparations · market cap $21.4B · as of 2026-10-16

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-03-15 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Genmab A/S is a Copenhagen-based antibody company with ADRs on NASDAQ, 3,119 employees, and a market cap of about $21.4B at roughly $37.82 per ADR. Unlike most companies under CatalystAlert coverage, it is profitable: 2025 revenue was $2,390M, net income $631M, and R&D spend $1,107M. Cash stands at $1,715M, and our data shows negative net debt of the same amount. Our database tags zalutumumab (Phase 3, head and neck cancer) as the lead asset. The dated catalyst calendar, however, is driven by epcoritamab, acasunlimab and several Phase 3 trial-arm readouts through 2027, following a positive Phase 3 readout on 2026-10-05.
The catalyst path
  • 2027-03-15 (est.)Phase 2 · Epcoritamabimp 7/10
  • 2027-04-30 (est.)Phase 2 · Epcoritamabimp 7/10
  • 2027-05-01 (est.)Phase 2 · Epcoritamabimp 7/10
  • 2027-06-15 (est.)Phase 3 · Vincristineimp 9/10
  • 2027-07-01 (est.)Phase 2 · Epcoritamabimp 7/10
  • 2027-07-30 (est.)Phase 3 · Acasunlimabimp 9/10
  • 2027-08-31 (est.)Phase 2 · Epcoritamabimp 7/10
  • 2027-09-15 (est.)Phase 2 · Epcoritamabimp 7/10
Pipeline
AssetPhaseIndication
gemcitabine and oxaliplatinPhase 2Diffuse Large B-Cell Lymphoma
GEN1042Phase 2Malignant Solid Tumor
tisotumab vedotinPhase 3Solid Tumor
ZalutumumabPhase 3Head and Neck Cancer
EpcoritamabPhase 3Diffuse Large B-Cell Lymphoma
Epcoritamab (monotherapy)Phase 2Diffuse Large B Cell Lymphoma
Rina-SPhase 3Endometrial Cancer
Enapotamab vedotin (HuMax-AXL-ADC)Phase 2Ovarian Cancer
GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cellsPhase 2Breast Cancer, Breast Neoplasms
AcasunlimabPhase 3Cutaneous Melanoma
GEN1286Phase 2Advanced Solid Tumor
Acasunlimab in combination with docetaxel (in a single expansion cohort)Phase 2Solid Tumors
HuMax-CD4Phase 2Cutaneous T-Cell Lymphoma
ErythromycinPhase 2High Grade Epithelial Ovarian Cancer
Pegylated liposomal doxorubicin (PLD)Phase 3Platinum-resistant Ovarian Cancer
VincristinePhase 3Follicular Lymphoma (FL)
Investigation agent 2Phase 2Relapsed Follicular Lymphoma
vinorelbinePhase 3Cervical Cancer
Doxorubicin HydrochloridePhase 2Non-Hodgkin Lymphoma
PetosemtamabPhase 3Left-sided Colorectal Cancer
Price & technical context
3-month
+56.4%
6-month
+93.6%
12-month
+68.6%
52-wk range
$23.85–$57.29
vs 50-day MA
+24.8%
vs 200-day MA
+62.9%
Realized vol
43.6%
Max drawdown
-32.5%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for GMAB (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.